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ABSTRACT OF DISSERTATION

CONTROLLED RELEASE OF OSTEOTROPIC MOLECULES
STIMULATES IN VITRO CELLULAR ACTIVITY AND
IN VIVO LOCAL BONE REGENERATION
Bone defects treatment and reconstructive surgery continues to increase at a
significant rate. Current bone defect treatments are autotransplantation, allograft,
and xenografts create many problems such as, inflammation, infection and
chronic pain. Moreover, allografts and xenografts arouse immune rejection.
These problems have led to development of controlled release system for use as
alternatives to autografts, allografts and xenografts in bone repair. There have
been many approaches for sustained drug delivery in local bone regeneration
using biodegradable polymers and osteotropic biomolecules. This dissertation
presents new approaches that apply intermittent drug delivery for local bone
regeneration. In the first, the osteotropic molecules simvastatin (Sim) or
parathyroid hormone (PTH) were released with intermittent profiles. In the
second, alternating delivery of Sim and PTH as well as alternating release of the
antimicrobial agent cecropin B (CB) with Sim or PTH. An association polymer
system of cellulose acetate phthalate (CAP) and Pluronic F-127 (PF-127) was
used for the delivery vehicle. Each device showed discrete peaks in release
profiles and lasted more than 10 days. Release profiles could be controlled by
altering surface area exposed to aqueous environment, number of layers, loading,
and blending ratios. Cells were cultured with sustained or intermittent exposure
to Sim or PTH at various concentrations, and alternating exposure to CB and Sim
or PTH and to Sim and PTH at different concentrations. Low dose Sim and PTH
treatments stimulated higher osteoblastic activity than observed in control
cultures. Furthermore, intermittent delivery was more effective than sustained
exposure. In vivo, newly formed bone was found in animals implanted with both
blank Sim-loaded devices. However, a greater anabolic effect was seen for Sim
release devices. Further, intermittent release devices stimulated the greatest
woven bone thickness, total bone area, and lamellar bone area. These results
suggest that intermittent release devices containing a single molecule, Sim or
PTH, and alternating release devices containing multiple molecules, CB with Sim

or PTH, possess promising potential as a treatment for local bone regeneration.
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INTRODUCTION
Bone loss is an important heath care problem worldwide and current bone
defect treatments have been mainly focused on replacing the lost bone with
allogeneic, xenogeneic or synthetic materials. The use of allogeneic or
xenogeneic tissue for bone repair involves immune rejection, and disease
transmission. Although autogenic bone grafts are the most successful, they also
face on additional surgery, and limitation of mount available. One approach to the
success of bone regeneration via tissue engineering strategies is the proper
design of the osteogenic molecule delivery devices. The requirements of devices
for bone regeneration should include controlled released, biodegradability,
mechanical integrity, and osteogenesis.
Controlled release technology has been studied for delivering a variety of
biomolecules at the proper time, with the proper amount, and to the proper site.
Most commonly,

investigators seek to release one drug at constant

concentrations for extended periods. However, non zero-order kinetics can be
more desirable than zero-order kinetics for delivery of biomolecules for local
bone regeneration.

Two osteotropic biomolecules of interest are simvastatin

(Sim), which is a widely used cholesterol-lowering drug, and parathyroid
hormone (PTH), which is well known for its role in calcium homeostasis. At the
systemic level, injections of Sim stimulate bone formation [1-6]. Intermittent or
pulsatile administration of PTH also has an anabolic effect [7-12], but sustained
treatment with PTH has catabolic effect on bone [13-15]. In this study, the
objective was to mimic the intermittent concentrations resulting from daily
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injections or oral dosing using controlled release methods.
An association polymer system based on blends of CAP and PF-127 was
previously investigated for providing pulsatile release of biomolecules [16].

It

was this CAP and PF-127 association polymer system that was used to develop
devices for intermittent release of osteotropic molecules. Because certain bone
defects can be contaminated with microorganisms, devices for delivery of
osteotropic molecules with an antimicrobial peptide was also examined.

This

dissertation reports characterization of the release systems, in vitro bioactivity,
and the bioactivity for select devices.

BACKGROUND
The need to treat bone defects resulting from degenerative diseases, trauma,
and reconstructive surgery continues to increase at a significant rate. Currently,
bone graft procedures exceed 500,000 in the US and approximately 2.2 million
worldwide [17]. Harvesting autogenous tissues needs an additional surgery at the
donor site that can result in its own complications, such as inflammation, infection,
and chronic pain.

Also, the total amount of bone that can be harvested is limited

and creates a supply problem. Although allograft tissue is treated by freezing,
freeze-drying, gamma irradiation, electron beam radiation, or ethylene oxide,
because it is obtained from a donor, a risk of disease transmission from donor to
recipient exists [18]. Xenografts are an alternative approach to helping patients,
but they still raise concerns with disease transmission and immune rejection.
These problems have led to development of drug delivery devices, synthetic
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materials, and tissue engineered constructs for use as alternatives to autografts
and allografts in bone repair.
i.

Bone Formation
a.

Intramembranous ossification

Intramembraneous ossification is the formation of bone on fibrous
connective tissue and involves making flat bones such as the mandible, skull,
and some irregular bones. The bone is formed from mesenchymal cells and is
first formed as connective tissue membranes. Osteoblasts proliferate and migrate
to the membranes and then differentiate and deposit bone matrix. They finally
turn into osteocytes and form Woven bone then produce osteons [19,20].
b.

Endochondral Ossification

Endochondral ossification happens in long bone formation such as the
femur and humerus. In this process, bone is firstly formed as hyaline cartilage.
The perichondrium which surrounds the hyaline cartilage is infiltrated with artery
and osteoblasts and changes into a periosteum. The osteoblasts form a collar of
compact bone around the diaphysis. Then, the cartilage in the center of the
diaphysis begins to disintegrate. Osteoblasts penetrate the disintegrating
cartilage and replace it with trabecular bone. This forms a primary ossification
center. Ossification continues from this center toward the ends of the bones.
After trabecular bone is formed in the diaphysis, osteoclasts break down the
newly formed bone to open up the medullary cavity. In epiphysis periosteal buds
recruit mesenchymal cells and blood vessels and the process is similar that in a
primary ossification center. This is secondary ossification center. Cartilage

3

between the primary and secondary ossification centers is the epiphyseal plate,
and this epiphyseal plate keeps on forming new cartilage. New cartilage, then, is
replaced by trabecular bone, and this process contribute to increase length of the
bone [19,20].
ii.

Controlled Release
The original goal and direction of controlled release technology is to

maintain appropriate concentrations of a single drug for extended periods.
Current drug delivery devices primarily utilize a variety of polymeric biomaterials,
such as polylactides (PLA), polyglycolides (PGA), poly(lactide-co-glycolides)
(PLGA), polyanhydrides, and polyorthoesters.

Mainly, micro- or nanospheres

and porous scaffolds have been developed for delivery devices and [21-32]. In
drug incorporating method, drug can be directly incorporated with delivery
devices physically or it can be bind by chemically-electrostatic [32], ionic bond
[33], or covalent bond [34] to devices.
Many approaches to intermittent biomolecules delivery have been
investigated, such as injections, oral dosing, pulmonary inhalation and,
transdermal delivery, [35-41]. In injections, patients may suffer from acute pain,
and compliance can be problematic for prolonged administration. Oral doing is
inefficient, because certain many parts of taken drugs can be destroyed in the
gastrointestinal tract before they reach plasma or they may be excreted.
Pulmonary inhalation requires continuous inhalation. As a result, a programmable
device that does not need additional actions is required.
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iii.

Drug release Kinetics
In most drug release, the rate of drug release changes when the release

continues. Initially the rate of release relatively large, while at very long times the
rate of release reaches to zero. In order to characterize the kinetic behavior of
drug release, it is required to determine how the rate of release varies as the
reaction progresses [42,43].
Rate law is differential equation because the rate of a drug release
depends on the rate of change of the drug release with time. The differential rate
law relates to the rate of drug release from the device to the system. Usually,
differential rate laws have many different forms, however, most drug release
kinetics belong to one of three differential rate laws [42,43].
a.

Zero-Order Release

For a zero-order release, the rate of drug release is a constant. When the
drug is completely consumed, the release abruptly stops.
Differential Rate Law:

r=k

Eq. 1

where k is rate constant, (L mole-1 sec-1).
b.

First-Order Release

For a first-order release, the rate of drug release is directly proportional to
the concentration of the drug ([A]). When the drug is consumed during the
release, the concentration and the rate of reaction reduces in the system.
Differential Rate Law:

r=ka

Eq. 2

where k is rate constant, (L mole-1 sec-1).
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c.

Second-Order Release

For a second-order release, the rate of drug release is directly
proportional to the square of the concentration of the drug ([A]). For this type of
release, the rate of release decreases rapidly (faster than linearly) as the
concentration of the drug decreases.
Differential Rate Law:

r = k [A]2

Eq. 3

where k is rate constant, (L mole-1 sec-1).
iv.

CAP and PF-127 Polymer System
Cellulose acetate phthalate (CAP) is a cellulose derivative that has been

used in the pharmaceutical industry for enteric coating of oral tablets and
capsules. While the regulatory status is clear for oral applications (i.e., in FDA
Inactive Ingredients Guide), it remains unknown with respect to parenteral
devices. However, Heller’s group has previously used CAP in formulations for
treating heroin addiction [44,45]. Pluronic F-127 (PF-127) is a triblock copolymer
of polyethylene oxide and polypropylene oxide. The numerous ether sites within
PF-127 allow for hydrogen bonding with carboxylic acid groups in CAP. Blends of
CAP and PF-127 form an association polymer that undergoes surface erosion
following deprotonation at physiological pH and consequently shows zero-order
release. In contrast to the commonly used biodegradable polyesters, such as
poly(lactide-co-glycolide), which undergo bulk hydrolysis, the CAP/PF-127
system degrades by surface erosion, in which the material degrades from the
outermost surface toward the inside [16]. The CAP/PF-127 polymer system can
be used for programmed drug delivery, with the rate, duration, and amount of
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released drug controlled by blending ratio, number of layers, and thickness
[16,46,47]
v.

Osteotropic Molecules
a.

Simvastatin

Sim is a well-known member of the statin family. Statins are potent prodrugs of hydroxy-3-methyl-glutaryl coenzyme A (HMG-CoA) reductase inhibitors
that block conversion of HMG-CoA to mevalonic acid, which is needed for
cholesterol biosynthesis [48]. Sim inhibits mevalonate, farnesyl pyrophosphate,
and geranylgeranyl pyrophosphate pathways [49], which are responsible for
increasing bone mineral density by reducing osteoclastic activity [50]. Statins
induce expression of bone morphogenetic protein 2 (BMP-2) in vitro, and they
stimulate bone formation on the calvaria of mice following daily subcutaneous
injections [1]. Oral dosing with Sim increases cancellous bone volume in rats [51],
and it also increases transverse area of fracture callus as well as mechanical
properties compared to controls [2]. Statins offer additional benefits, such as
promotion of new blood vessel growth [52] and anti-inflammatory effects [53].
Some literature show skeptical result of Sim on bone formation [54,55].
They investigated oral dosing and systemic effect of Sim. However, many studies
which carried local delivery of simvastatin showed positive effects on bone
formation not only in vitro but also in vivo. The main difference between systemic
and local delivery of simvastatin is effective concentration on the wound site.
Former is absorbed by gastro-intestine system and mainly works in the liver and
the latter works directly on the wound site. With 60 mg dosage forms, serum
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concentrations of Sim and simvastatin acid are 18.7 +/- 4.7 ng/ml and 3.5+/-0.5
ng/ml, respectively. Further, the half-life of simvastatin acid is 5.9 +/- 0.3 hr [56].
In local delivery of Sim, we can keep the Sim concentration as high as we can.
From the result of our study about in vitro simvastatin release [46], we can keep
the local Sim concentration around 100 ng/ml-210ng/ml.
Sim has a very low aqueous solubility, approximately 1.4 µg/mL [57],
because it has a rigid and hydrophobic section that is covalently linked to the
HMG-like moiety. It has an inactive lactone ring in HMG-like portion. In vivo, this
inactive lactone ring is enzymatically hydrolyzed to its active hydroxyacid form
[58]. To increase local concentration of Sim, it is hydrolyzed to cleave the lactone
ring and convert the molecule to its β-hydroxyacid form [59].
b.

Parathyroid Hormone

PTH 1-34 fragment is well known for its role in calcium homeostasis, and
PTH (1–34) delivery has either an anabolic or catabolic effect on bone,
depending on mode of delivery. It has been reported that daily injections of low
doses of PTH (1–34) stimulate bone formation and increase bone mass in
humans and animals [7,12,14,60-63], whereas continuous administration of PTH
(1–34) has a catabolic effect

[8,9,15,64]. Many in vivo and in vitro studies have

been conducted to explain the anabolic effect of PTH (1–34) on bone formation,
and it is clear that PTH (1–34) enhances proliferation of primary osteoblastic cells
from humans and animals in vitro [65,66]. In addition, PTH (1–34) exerts diverse
effects on osteoblast differentiation depending on differentiation stage [67,68],
and as a result, PTH (1–34) stimulates alkaline phosphatase (AP) activity in the
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mouse osteoblastic cell line MC3T3-E1 [68].
Intermittent administration of PTH shows anabolic effect on bone
formation by increasing number of osteoblasts [69-72], but the entire cellular
mechanisms involving this effect are still not fully understand. Many literatures
have shown that PTH activates survival signaling on osteoblasts and that result
delays of osteoblastic apoptosis. This is a main way to increasing osteoblast
number. PTH stimulates multiple intracellular signal pathways, mediated by cAMP,
and activates both protein kinase A (PKA) and C (PKC) [73]. PTH activates βarrestin and β-arrestin activates extracellular regulated kinase (ERK) signaling
[74,75]. β-arrestin is involved in desensitization of cAMP signaling by PTHr.
There are significantly fewer PTH receptors on osteoclast cells compared
to osteoblast cells. Consequently, osteoclast cells are indirectly affected by PTH
[76]. PTH binds to osteoblast cells and stimulates expression of receptor
activator of nuclear factor kappa B ligand (RANKL). RANKL binds to osteoclast
precursors with receptor activator of nuclear factor kappa B (RANK), and
stimulates these precursors fusing and forming new osteoclasts cells [77].
The plasma half life of intact PTH (1–34) is less than 11 min [36]. The fast
metabolic degradation of PTH requires multiple administrations of PTH to keep
the effective concentration in the plasma [78]. For example, plasma levels of PTH
in rats treated by pulmonary inhalation were elevated for less than 120 min
[36,79].

However, local application of relatively small amount of biomolecules

will have different requirements.
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vi.

Antimicrobial Agents
Regeneration of bone defects is complex and involves many sequential

cascades of events [80]. Furthermore, they may be faced with the threat of
microbial infection. Once an infection is established, it is difficult to solve the
problem. Treatment of deep infections requires multiple surgeries, prolonged
antibiotic treatment, and long-term problems [81]. Therefore, every effort is
required to prevent this problem with early treatment.
Continuous use of antibiotics results in increasing resistance to
antimicrobial drugs, including the occurrence of bacterial strains which are
resistant to antibacterial agents and has created a public health problem of
potentially crisis proportions (58). Antibiotic resistance is an evolution via natural
selection. The antibiotic action is a kind of environmental pressure and those
bacteria have a mutation allowing them to survive and reproduce, resulting in a
fully resistant generation [82,83]
Cecropin B (CB) is a naturally occurring cationic amphipathic insect
peptide [84,85] that can notably act not only against certain gram-positive
bacteria but also against gram-negative bacteria, fungi, and parasites [86-88].
The mechanism of action of cecropin B involves channel formation in
membranes and subsequent lysis [89]. CB has a broad spectrum of EC50 (half
maximal effective concentration; the concentration of a drug which responses
half from the baseline to maximum) from 1µM to 20µM, depending on
microorganism and fungi [86,90,91].
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vii.

Delivery of Multiple Molecules
Because multiple cascades are required to direct the processes involved

in bone repair to completion, the success of most current research focusing on
delivery of a single biomolecule may be limited [92]. A method to overcome
limitation of single molecule delivery is to release multiple molecules with distinct
kinetics to trigger the tissue regeneration at the proper site of action [92,93].
One of the polymeric multiple biomolecules delivery systems is the use of
scaffolds and drug loading methods into the scaffolds is that one molecule is
mixed in scaffold and another drug was encapsulated into microspheres. In this
method Mooney’s group investigated dual growth factors delivery using PLGA
scaffold for 40 days. Another approach was made by Mikos’ group, they
encapsulated dual growth factors and crosslinked them each other [94]. They
seek for the target of traditional controlled release system-simultaneous
sustained release system, whereas our devices aimed at short term intermittent
delivery.
viii.

Significance and Objectives
Sim has an anabolic effect on bone formation, especially when

intermittently administered. Similarly, intermittent/pulsatile delivery of PTH can
promote bone formation, whereas it is destructive is constantly administered.
There are few studies about local delivery of Sim or PTH with biodegradable
polymeric devices. Furthermore, there has been no study related to devices
combining release of Sim and PTH or such devices combined with an
antimicrobial agent, such as CB.

Developing devices for intermittent delivery of
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single or multiple osteotropic and antimicrobial molecules for placement in bone
defects may lead to better treatments for local bone regeneration.
The objectives of these studies were to develop devices that intermittently
or sustained release of single molecule (Sim or PTH) and multiple releases of
molecules (CB/Sim, CB/PTH, or Sim/PTH). The hypotheses were that the mode
of local Sim release affects in vitro osteoblastic activity and in vivo bone
formation and that the mode of local PTH(1-34) release affects osteoblastic
activity. To test these hypotheses, devices for intermittent delivery of Sim or
PTH(1-34) were developed, and they were demonstrated that the cellular effects
of Sim or PTH(1-34) on osteoblastic proliferation and differentiation were
dependent on mode of administration and degree of new bone formation relied
on mode of release of Sim.

12

Chapter One

BIOERODIBLE DEVICE FOR INTERMITTENT RELEASE OF
SIMVASTATIN ACID

1.1

INTRODUCTION

The need to treat bone defects resulting from degenerative diseases,
trauma, and reconstructive surgery continues to increase at a significant rate.
More than 500,000 bone grafting procedures are performed annually in the
United States [95]. Harvesting autogenous tissues requires an additional surgery
at the donor site that can result in its own complications, such as inflammation,
infection, and chronic pain. Also, the total amount of bone that can be harvested
is limited and creates a supply problem. Although allograft tissue is treated by
freezing, freeze-drying, gamma irradiation, electron beam radiation, or ethylene
oxide, because it is obtained from a donor, a risk of disease transmission from
donor to recipient exists [18]. These problems have led to development of drug
delivery devices, synthetic materials, and tissue engineered constructs for use as
alternatives to autografts and allografts in bone repair.
Simvastatin is a well-known member of the statin family. Statins are potent
pro-drugs of hydroxy-3-methyl-glutaryl coenzyme A (HMG-CoA) reductase
inhibitors that block conversion of HMG-CoA to mevalonic acid, which is needed
for cholesterol biosynthesis [48]. Simvastatin occupies a portion of the binding
site for HMG-CoA, thus blocking access of substrate to the active site [96].

13

Mevalonic acid is a precursor not only of cholesterol but also of isoprenoids, such
as geranyl pyrophosphate, which is important in the control of osteoclastmediated bone resorption [97]. Statins offer additional benefits, such as
promotion of new blood vessel growth (Kureishi et al., 2000) and antiinflammatory effects [53]. Most relevant to the present work, Mundy’s group
originally demonstrated that statins induce expression of bone morphogenetic
protein 2 (BMP-2) and that they stimulate bone formation on the calvaria of mice
following daily subcutaneous injections [1]. Subsequent studies have shown that
oral dosing with simvastatin increases cancellous bone volume in rats [51], and it
also increases transverse area of fracture callus as well as mechanical properties
compared to controls [2].
For local delivery of simvastatin, typical controlled release devices that
attempt to achieve zero-order kinetics may not be the most effective. To mimic
alternating concentrations resulting from daily injection or oral dosing, devices
providing intermittent release profiles would be useful. We previously
investigated an association polymer system based on blends of cellulose acetate
phthalate (CAP) and Pluronic F127 (PF-127) for providing pulsatile release of
macromolecules [16].
The objectives of this study were to develop devices that intermittently
release simvastatin acid and demonstrate that exposure of osteoblastic cells to
alternating concentrations of the drug enhances bioactivity.
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1.2
1.2.1

MATERIALS AND METHODS

Hydrolysis of Simvastatin
To decrease hydrophobicity of simvastatin (Aldrich, Milwaukee, WI), 42

mg were dissolved in 1 ml of 95% ethanol, and 1.5 ml of 0.1 M NaOH was added.
The solution was heated at 50°C for 2 hours.

Then the final solution was

neutralized to pH 7.2 with 0.1 M HCl, and the volume was brought to 10 ml with
deionized water [59]. Simvastatin acid (10 mM) was stored frozen at -20°C.
1.2.2

CAP/PF-127 Microspheres
Microspheres containing different weight fractions of CAP (Fluka, Buchs,

Switzerland) and PF-127 (Sigma, St Louis, MO) were prepared by a wateracetone-oil-water (W/A/O/W) triple emulsion process. Two g of different polymer
blends of CAP and PF-127 (7:3, 6:4 and 5:5 by weight of CAP:PF-127) were
dissolved in acetone. One ml of phosphate-buffered saline (PBS), pH 7.4, with or
without 100 μM simvastatin acid was added to the acetone solution and mixed
into rapidly stirring corn oil and sonicated. The CAP/PF-127 suspension and 5%
Triton X-100 were added to deionized water and then stirred to harden the
microspheres for 5 minutes. Following collection, microspheres were washed
three times with deionized water, filtered, and dried in vacuum up to seven days.
Release devices were made using a pressure-sintering process.
Microspheres were first treated by UV radiation in a laminar flow hood for 30
minutes. Ten to 15 mg of UV-treated microspheres containing simvastatin acid
were placed in the wells of a Delrin mold (diameter, 6.2 mm; depth, 20 mm) and
consolidated by applying 20 MPa pressure for 5 sec. Next, blank microspheres
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were added on top of the first layer, and pressure was reapplied. By repeating
this process, six-, eight-, and ten-layer devices were prepared.

To provide

directional control of drug release, the bottom and sides of the devices were
coated three times with 10% poly(lactic-co-glycolic acid) (75:25, Mw~75 kDa;
Alkermes, Cincinnati, OH) solution in methylene chloride.
1.2.3.

In Vitro Release
Samples were immersed in 5 ml of 150 mM PBS, pH 7.4, and incubated at

37ºC under either static or dynamic (shaking at 80 rpm) conditions using a MaxQ
Mini 4450 shaker (Barnstead/Lab-Line, Dubuque, IA).

Supernatant was

collected and replaced daily to maintain a constant volume. To allow
quantification of released simvastatin acid, CAP was precipitated from the 1 ml of
supernatant samples by treatment with 0.1 ml of 0.1 M hydrochloric acid. Acidtreated supernatants were then centrifuged at 1000 rpm for 5 minutes. Solutions
were placed into 96-well assay plates, along with simvastatin acid standards
made by serial diluting from a 1 mM stock solution. The concentration of
simvastatin acid was determined fluorometrically using a SpectraMAX Gemini
XS ( λex=390 nm, λem=413 nm).
Profiles were predicted using the approach of [47], who proposed the use
of nonuniform initial concentration distributions as a means to regulate the
release of biomolecules from drug delivery devices.

For erosion-controlled

systems, Eq. 1 describes the fractional release from a planar sheet with initial
biomolecule distribution f(x), half-thickness a, and erosion rate constant B.
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∫
∫
a

M
=
M∞

a − Bt
a
0

1.2.4

f ( x ) xdx

Eq. 1

f ( x ) xdx

Cell Culture
MC3T3-E1 preosteoblastic cells (CRL-2593; ATCC, Manasas, VA) were

seeded at a density of 15,000/cm2 into 24-well tissue culture plates in α Minimum Essential Medium (MEM) containing 10% fetal bovine serum
(GIBCO/Invitrogen, Carlsbad, CA), 50 µg/ml ascorbic acid (Sigma), 5 mM ßglycerophosphate (Sigma), and 0-1 µM simvastatin acid.

In a deviation from

previous simvastatin treatment studies in the literature, medium was exchanged
every day.

In sustained release cultures, cells were constantly exposed to

simvastatin acid at a fixed concentration, i.e., the medium always contained the
same concentration of drug.

In intermittent release cultures, cells were exposed

to alternating concentrations, i.e., the medium varied between simvastatincontaining and drug-free medium. Multiple dilutions of simvastatin acid were
selected based on preliminary cytoxicity studies.

Medium in control cultures

was changed on the same schedule, but it did not contain simvastatin acid at any
time.
1.2.5

Assays
After 3, 7, 10, and 14 days of culture, cells were rinsed twice with PBS and

then lysed by sonication in a high salt solution (0.05M NaH2PO4, 2M NaCl, and
2mM EDTA). DNA standards were prepared by serial diluting calf thymus DNA in
the high salt solution. Hoechst 33258 (final concentration, 0.5 µg/ml; Sigma) was
added to DNA standards and samples and allowed to react in the dark for 10
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minutes [16,98].

The amount of DNA in the samples was determined by

measuring fluorescence (λex=356 nm, λem=458 nm).
To measure alkaline phosphatase (AP) activity, cell lysate was incubated
with substrate solution prepared by dissolving 10 mM of p-nitrophenyl phosphate
(Sigma) in 0.6 M 2-amino-2-methyl-1-propanol buffer, pH 10 [16]. After 30
minutes, 0.25 N NaOH was added to each well to immediately stop enzyme
activity. Absorbance at 410 nm was measured with an MR5000 microplate reader
(Dynatech Laboratories, Chantilly, VA), and the amount of substrate cleaved was
determined using ε=1.7x104 M-1cm-1. Activity was expressed as nmol of substrate
cleaved per minute and then normalized by DNA content.
For measuring osteocalcin (OCN) secretion, conditioned medium was
assayed using an EIA kit (Biomedical Technologies, Stoughton, MA) following the
manufacturer’s protocol.

Concentrations were determined from a standard

curve constructed using mouse OCN.
1.2.6

Statistical Analysis
Results (mean and standard deviation) were calculated from at least six

replicate samples. One-way analysis of variance (ANOVA) was conducted using
the computer application InStat (Graphpad Software, San Diego, CA). Post-hoc
comparisons were made using the Tukey-Kramer test when the p-value was
significant (p<0.05).
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1.3
1.3.1

RESULTS

Release Profiles
To create intermittent release profiles, drug-loaded microspheres were

alternately layered with blank (unloaded) microspheres.

Microspheres were 50-

150 µm in diameter and had a loading of 68-73 ng simvastatin acid per mg of
polymer. By multilayering blank and loaded microspheres, six-, eight-, and tenlayer devices had approximate totals of 3, 4, and 5 µg simvastatin acid,
respectively.

Figure 1.1 shows both the designed/predicted and experimentally

determined release profiles for 10-layer devices.

In general, the shape and

duration of the experimental profile were comparable to those of the
desired/predicted release profile.

Two differences were noted, however.

Whereas the designed profile had zero release between the peaks, small
amounts of simvastatin acid were measured.

In addition, the peak release

values were not identical to those predicted in the model.

Regardless, the

desired intermittent release profiles were obtained.
Figure 1.2 shows cumulative release of simvastatin acid for the three
different blend ratios under dynamic release conditions.
linear.

All three profiles were

The polymer with the highest ratio of CAP to PF-127 (7:3) had a slightly,

but significantly (p<0.05), slower release rate.

This blend also lasted for a

longer time, approximately two days longer. Behavior of the 5:5 and 6:4 blends
was statistically similar.

And although differences were observed in the rate and

duration of release, statistically similar total amounts of simvastatin acid were
delivered for all blends.
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Experimental

Model

Simvastatin Release (μM)

0.3
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20

Time (Days)
Figure

1.1.

Comparison between the desired/predicted and the

experimental release profiles for 10-layer devices (7:3 CAP:PF-127).

Figure 1.3 shows the effect of CAP to PF-127 blend ratio on intermittent
release of simvastatin acid under dynamic conditions. All three devices showed
exactly five discrete peaks, with each layer degrading over two to three days.
As expected from Figure 1.2, 7:3 blends lasted slightly longer than did 5:5 and
6:4 devices.
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Simvsatatin Release (Fractional)0

1.2
1
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0.6
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6:4
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14

Time (Days)

Figure 1.2.
acid.

Effect of blend ratio on cumulative release of simvastatin

Data are the mean of at least six replicates.

Error bars, which

ranged from 3-11% of the mean, are not shown to prevent obscuring the
curves.

The number of layers can be altered to modulate release (Figure 1.4).

Six

layer devices had exactly three discrete peaks, eight layer devices had four
peaks, and ten layer devices had five peaks under dynamic release conditions. In
these experiments, each layer lasted approximately two days, independent of the
number of layers.
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0.8

Simvsatatin Release (μM)

0

5:5
6:4
7:3

0.6

0.4

0.2

0
0

5

10

15

Time (Days)
Figure

1.3.

Effect of blend ratio on intermittent release of

simvastatin acid from 10-layer devices. Data are the mean of at least six
replicates. Error bars, which ranged from 5-9% of the mean, are not shown
to prevent obscuring the curves.

The release conditions were also found to affect the kinetics of polymer
erosion and subsequent release of simvastatin acid (Figure 1.5). Five discrete
peaks were seen when samples were degraded under both static and dynamic
conditions.

Under static release conditions, however, 10-layer devices lasted for

more than 20 days, compared to only 12 days under dynamic conditions.
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Figure

1.4.

Effect of number of layers on intermittent release of

simvastatin acid (blend ratio, 7:3).

Data are the mean of at least six

replicates. Error bars, which ranged from 3-14% of the mean, are not shown
to prevent obscuring the curves.

1.3.2

Cytotoxicity
Degradation products from polymer erosion experiments (i.e., dissolved

CAP and PF-127 in the PBS) were diluted in cell culture medium and added to
MC3T3-E1 osteoblastic cells (Figure 1.6). The undiluted release supernatant
was considered 100%, and increasing dilutions into the cell culture medium were
tested. High concentrations of CAP/PF-127 had a cytotoxic effect, causing cell
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death. Even 40% degradation products had a time-dependent, adverse effect
on the cells (p<0.01). While cell responses were similar within the first two days
of exposure, cytotoxic effects became apparent by four days.

At 20% and below,

however, the cells were unaffected; both the DNA content (reflecting number of
cells) and production of alkaline phosphatase (reflecting bioactivity) were
statistically similar to levels in control cultures.

Simvsatatin Release (μM) 0

0.6
Static Release

0.5

Dynamic Release
0.4
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0.1
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0

5

10
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20

25

Time (Days)

Figure

1.5.

Effect of incubation conditions on intermittent release of

simvastatin acid from 10-layer devices (blend ratio, 7:3).
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1.6.

1
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8

Effect of CAP/PF-127 (7:3) degradation byproducts on

osteoblastic cells.

1.3.3

Cell Responses to Alternating or Constant Concentrations of

Simvastatin Acid
Having determined acceptable levels of degradation products, effects of
different profiles of exposure to simvastatin acid were investigated. DNA content
and alkaline phosphatase (AP) activity in MC3T3-E1 cultures exposed to
pulsatile/alternating and sustained/constant delivery of simvastatin acid are
shown in Figure 1.7. In all groups, except 1 µM constant concentration, the
amount of DNA increased until the seventh day, and the growth rates were
somewhat diminished afterward. Intermittently exposing cells to 1 µM simvastatin
acid reduced, but did not eliminate, the adverse effect of this higher
concentration.

Alternating exposure to lower concentrations of simvastatin acid

increased DNA contents in the earlier stage of culture (p<0.05). AP was elevated
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by intermittent exposure to simvastatin acid.

Activity was significantly higher for

the 100 pM and 10 nM alternating groups at 10 days compared to the other
treatments (p<0.05).
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5
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10nM-alt

10nM-con
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0.3
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4
3
2
1
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100pM-con
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3

14

Figure

1.7.
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Time (Days)

DNA content and alkaline phosphatase activity for

osteoblasts exposed to constant and alternating simvastatin acid.

Results for OCN secretion by MC3T3-E1 cells exposed to alternating and
constant delivery of simvastatin acid and the controls are shown in Figure 1. 8. In
control cultures, OCN levels remained relatively constant at low concentration
(p<0.05). At day 1, cells constantly exposed to simvastatin acid showed higher
concentrations of OCN compared to controls and close to levels in cells exposed
to alternating simvastatin acid.

At days 2 and 4, cells constantly exposed to

simvastatin acid showed decreased concentrations that then remained fairly
constant (p<0.05). For 1 µM constant exposure, levels of secreted OCN were
dramatically decreased compared to the 100 pM and 10 nM constant
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concentrations. All cells intermittently exposed to simvastatin acid showed
increased OCN concentrations in the earlier stage of culture (p<0.05), and levels
remained high. Concentrations were significantly higher for the 10 nM and 1 µM
alternating groups after 2 days in comparison with the other groups (p<0.05).

Control
100pM-alt

OCN Expression (ng/ml) 0

80

100pM-con
10nM-alt

10nM-con
1µM-alt

1µM-con

60

40

20

0
1

Figure 1.8.
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Osteocalcin secretion for osteoblasts exposed to constant

and alternating simvastatin acid.

1.4

DISCUSSION

Simvastatin has an HMG-like moiety, which is present as an inactive
lactone.

In vivo, this prodrug is enzymatically hydrolyzed to its active

hydroxyacid form [58].

Simvastatin also has a rigid, hydrophobic section that is

covalently linked to the HMG-like portion. Consequently, the drug has a very low
aqueous solubility, approximately 1.4 µg/ml [57]. More hydrophilic molecules can
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give a higher local concentration. Therefore, the approach used for enhancing
simvastatin solubility was hydrolysis to cleave the lactone ring and convert the
molecule to its β-hydroxyacid form [59]. The hydroxyacid form of simvastatin is
approximately three orders of magnitude less lipophilic than the lactone form [99].
Cellulose acetate phthalate (CAP) is a cellulose derivative that has been
used in the pharmaceutical industry for enteric coating of oral tablets and
capsules. While the regulatory status is clear for oral applications (i.e., in FDA
Inactive Ingredients Guide), it remains unknown with respect to parenteral
devices. However, Heller’s group has previously used CAP in formulations for
treating heroin addiction [44,45].
Pluronic F-127 (PF-127) is a triblock copolymer of polyethylene oxide and
polypropylene oxide. The numerous ether sites within PF-127 allow for hydrogen
bonding with carboxylic acid groups in CAP. Blends of CAP and PF-127 form an
association polymer that undergoes surface erosion following deprotonation at
physiological pH and consequently shows zero-order release.
In contrast to the commonly used biodegradable polyesters, such as
poly(lactide-co-glycolide), which undergo bulk hydrolysis, the CAP/PF-127
system degrades by surface erosion, in which the material degrades from the
outermost surface toward the inside [16,47]. Therefore, the overall shape of the
release profiles was linear. When alternating loaded and unloaded layers, flatter
regions reflecting erosion of the blank layers were also observed.
As a non-ionic surfactant, PF-127 is readily soluble in water, but CAP is
swelled and then relatively slowly dissolved in neutral solutions. Consequently,
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blends containing higher ratios of PF-127 had shorter duration delivery profiles.
But the overall effect was small, in contrast to the work of Lee, in which larger
differences in erosion were observed for the different blends[47,100]. This
discrepancy may be related to structural differences resulting from the fabrication
methods. Lee and associates made their devices by simply solvent casting,
whereas in the present work, CAP/PF-127 microspheres were made first and
then pressure-sintered into multilayered devices. Another reason for the different
degradation rates may be the exposed surface area. Lee’s samples were
exposed on both top and bottom surfaces, so the degradation rate was relatively
higher compared to the present devices, which were coated to protect all but one
surface from the aqueous environment. Differences in the carboxylate content of
CAP obtained from different sources may also have affected material
degradation.
Directional control of release was obtained by coating with a more
hydrophobic biodegradable polymer(PLGA). Poly Lactic acid(PLA) also can be
considered as a coating materials, however the degradation rate of PLA is more
than a year [101], consequently, PLA should be remained on the implant site for
long period of time after CAP/PF-127 device degradation. It is not necessary that
coating material remains on the implant site after delivery device degradation.
Thus, only one surface was exposed to PBS, and as mentioned previously, the
degradation rate was consequently reduced. The total duration of delivery
depended directly on the number of layers and the release environment. For
each additional set of blank and loaded layers, another release peak was
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obtained. Even gentle mechanical agitation enhanced erosion of the polymer.
These results indicate that, in addition to chemical dissolution effects, physical
erosion also plays a role in degradation of CAP/PF-127. Therefore, even though
intermittent release will be obtained, the duration of delivery will depend on the
site of implantation. Consider, for example, low clearance of erosion byproducts
following placement in a relatively confined bony defect compared to an implant
more vigorously bathed in body fluids.
Comparison of the present doses to those used clinically is complicated by
the significantly different uses of simvastatin:
vs. stimulation of local bone formation.

systemic lowering of cholesterol

The clinically recommended therapeutic

dose of simvastatin ranges from 5 to 80 mg/day. With 60 mg dosage forms,
serum concentrations of simvastatin and simvastatin acid are 18.7 +/- 4.7 ng/ml
and 3.5+/-0.5 ng/ml, respectively.

Further, the half-life of simvastatin acid is 5.9

+/- 0.3 hr [56]. The devices described in the present work released simvastatin
acid at a rate of approximately 36.5 ng/hr into 5 ml of PBS.

To stimulate bone

formation in animals, Mundy et al. [1] injected 1-10 mg/kg/day subcutaneously
over the calvaria of mice for 5 days.

Assuming 30 g animals, up to

approximately 300 μg of simvastatin was administered each day.

In contrast,

the present devices contained up to only 5 μg of simvastatin acid.
As might be expected with many biodegradable/bioerodible materials, high
levels of degradation byproducts can be cytotoxic. This has been welldocumented for polymers and copolymers of lactic and glycolic acid [102-105].
When biodegradable materials are implanted, however, the concentration of toxic
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byproducts is reduced via dilution in extracellular fluids and blood and by
clearance via the circulatory and lymphatic systems.

In the present work,

although high concentrations of degradation products were cytotoxic, dilution of
CAP/PF-127 byproducts to less than 40% prevented adverse effects.
Preliminary results following implantation of CAP/PF-127 release devices in rats
show no evidence of adverse effects (data not shown).
The results of DNA content, AP activity, and OCN secretion for
preosteoblastic cells exposed to intermittent and sustained concentrations of
simvastatin acid at lower concentrations (100pM - 10nM) indicate an anabolic
effect. The continued inhibition of HMG-CoA reductase activity and therefore of
cholesterol synthesis resulting from high, sustained concentrations of simvastatin
acid appear to have adversely affected the cells and prevented growth and
activity.

After Mundy and colleagues [1] reported that simvastatin induced

expression of BMP-2 in a model reporter system, Maeda et al. [51] showed that
continuous low doses of simvastatin enhanced AP activity and mineralization and
increased BMP-2 production in MC3T3E-1 cells.
In the present work comparing alternating exposure with constant
treatment, the former stimulated higher osteoblastic activity. This result is similar
to that for Mundy’s delivery via subcutaneous injection and the resulting local
pulsatile simvastatin profile that was found to enhance bone formation. Skoglund
and associates delivered simvastatin by daily oral dosing and found that
simvastatin-treated mice had a larger transverse area of fracture callus, and the
force required to break the bone was greater than controls [2]. Many clinical
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studies have suggested that statins are related to an increase in bone mineral
density and significantly reduced fracture risk [106,107].

1.5

CONCLUSION

Intermittent release of simvastatin acid was achieved using the association
polymer system of CAP and PF-127. The release profiles roughly mimic local
exposure resulting from repeated oral dosing or subcutaneous injections.
Furthermore, the release profiles can be controlled by varying polymer blending
ratio, number of layers, and release conditions. Cell number, alkaline
phosphatase activity, and osteocalcin secretion were enhanced in preosteoblastic
cell cultures treated with alternating concentrations of simvastatin acid.
Ongoing studies are directed at evaluating the bioactivity of intermittently
released simvastatin acid in vivo.

Overall, CAP/PF-127 devices can be

designed to provide pulsatile release of simvastatin acid, and such alternating
concentrations stimulate osteoblastic activity.

These devices may be useful for

promoting local bone formation.

Copyright © Ju Hyeong Jeon 2007
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Chapter Two

LOCALIZED INTERMITTENT DELIVERY OF SIMVASTATIN ACID
STIMULATES BONE FORMATION IN VIVO

2.1

INTRODUCTION

Stimulation of local bone formation using pharmacological compounds
that upregulate synthesis of autogenous bone growth factors is a promising
approach to treatment of bone defects. This method can lead to cost-effective
devices and less complicated surgeries [3].

Application of growth factors,

including bone morphogenetic protein-2 (BMP-2), can powerfully stimulate bone
formation. However, such recombinant proteins are expensive and when
exposed to a physiological environment, they can be degraded rapidly [108].
Furthermore the supraphysiological amounts needed may cause immune
responses [109].
Simvastatin is a member of the statin family of 3-hydroxy-3-methylglutaryl
coenzyme A (HMG-CoA) reductase competitive inhibitors, which are widely used
as cholesterol-lowering drugs. Simvastatin promotes bone formation both in vitro
and in vivo in animal models, associated with increased expression of BMP-2
[48,51,110]. In addition, simvastatin inhibits mevalonate, farnesyl pyrophosphate,
and geranylgeranyl pyrophosphate pathways [49,111,112], which are responsible
for bone formation by reducing osteoclastic activity [50]. This inhibition
mechanism plays an important role in the stimulation of bone mass by

33

simvastatin.
Currently available simvastatin is chemically modified from naturally
existing lovastatin. It has been developed for oral administration and to be
hepatoselective to decrease cholesterol synthesis in the liver. When delivered via
systemic circulation, simvastatin shows poor distribution to bone defect sites
[110]. Consequently, developing a simvastatin delivery device that provides
active amounts of drug with an appropriate time course to a desired site may be
more biologically effective.
Unlike traditional controlled release devices, which often aim to achieve
zero-order kinetics for constant concentration in the plasma, subcutaneous
injection and oral administration show pulsatile drug concentration profiles. In a
previous paper, we developed a device for intermittent release of simvastatin acid
using an association polymer system of cellulose acetate phthalate (CAP) and
Pluronic F-127 (PF-127). Pulsatile release profiles were demonstrated, and in
vitro stimulation of preosteoblastic cell activity was shown [46].
Based on prior results, the objective of the present study was to
investigate the ability of devices for controlled, localized delivery of simvastatin
acid, either with intermittent or sustained release, to stimulate localized bone
formation in a rat calvarial onlay model.
2.2
2.2.1

MATERIALS AND METHODS

CAP/PF-127 Microspheres and Release Devices
CAP/PF-127 microspheres and release devices were fabricated as

reported

previously

[46]

and

are

briefly
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described

here.

Drug-loaded

microspheres were made using a triple emulsion process to have a loading of 50
ng simvastatin acid per mg of polymer. Intermittent release devices were then
made by alternating 20 mg layers of microspheres loaded with simvastatin acid
and blank microspheres (without drug) (Figure 2.1). Sustained release devices
were made in the same manner, but every 20 mg layer contained simvastatin
acid. Control (blank) devices were made with the same amount of microspheres
used in sustained and intermittent release devices, however no drug was present.
To provide directional control of drug release, the bottom and sides of all devices
were coated with 10% poly(lactic-co-glycolic acid) (75:25, Mw~75 kDa; Alkermes,
Cincinnati, OH) solution in dichloromethane. To verify release profiles, devices
were incubated in 150 mM phosphate-buffered saline at 37ºC with gently shaking,
and simvastatin concentrations were determined fluorometrically [46].

2.2.2

Animal Procedures
Two month old male Sprague-Dawley rats were used in this study. A

calvarial onlay model was used to determine effects of local delivery of
simvastatin acid. Blank (no drug) devices (n=10), intermittent devices (n=10), and
sustained devices (n=10) were tested. After anesthetization, a transverse incision
was made toward the posterior end of the skull. The periosteum was reflected,
and implants were placed directly on the calvarium, with the exposed drugreleasing side of the devices facing the bone. Incisions were closed with three
sutures.
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2.1. Schematic representation of intermittent (A) and sustained

release devices (B).

2.2.3

Histological Preparation
After 9, 18, or 28 days, rats were euthanized, and the calvaria were

harvested. Specimens were immediately stored in 10% buffered formalin
phosphate (Fisher Scientific, Fair Lawn, NJ) solution for at least one week.
Samples were decalcified overnight in 5% nitric acid, dehydrated in an alcohol
series, and embedded in paraffin. Five μm thick coronal cross-sections were cut,
before staining with hematoxylin for 15 minutes and eosin for 15 seconds to 2
minutes then dehydrate in 95% absolute alcohols for transmitted optical
microscopy evaluation.
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2.2.4

Histological Analysis
Representative sections from the control, sustained release, and

intermittent release groups were examined at 40X and 100X magnification with
an Olympus IX51 inverted microscope with Insight digital camera (Diagnostic
Instruments, Sterling Heights, MI). In addition to qualitative assessments, the
thickness and total area of newly formed woven bone, the thickness relative to
implant center, and area percentage of lamellar bone islands within the woven
bone layer were determined. Thickness measurements were made on at least six
samples with 5 different regions in each group. Area calculations were based on
examination of 3 different 1 mm2 spots from at least six samples in each group.
ImageJ software (National Institutes of Health, Bethesda, MD) was used for
quantification.
2.2.5

Statistical Analysis
Data are presented as mean ± standard deviation of up to nine

measurements.

All histological measurements were compared among groups

by analysis of variance (ANOVA) using InStat (Graphpad Software, San Diego,
CA). Post-hoc comparisons were made using the Tukey-Kramer Comparison
Test when the p-value was significant (p<0.05).

2.3 RESULTS
2.3.1

Release Profiles
The approximate loadings of simvastatin acid were 5 μg for intermittent

release devices (5 drug-loaded layers at 1 μg/layer) and 10 μg for sustained
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release devices (10 loaded layers at 1 μg/layer). Figure 2.2 shows profiles for
release of simvastatin acid from the intermittent and sustained delivery devices.
As expected from their design, intermittent release devices exhibited five discrete
peaks separated by two to three days.

In contrast, for sustained release

devices, the concentration of simvastatin acid increased over the first 24 hours
and remained relatively constant for the next ten days. Both devices achieved
similar maximum concentrations and lasted for comparable durations.

2.3.2

Clinical and Physical Examination

During the postoperative healing period, wound dehiscence occurred in 3 rats (1
in each group), and infections resulting from bites from cage mates were
observed in 3 rats (2 in blank group and 1 in sustained one). As a result, 7 control,
9 intermittent, and 8 sustained specimens were available for histological analysis.
All animals gained weight (up to 50 g) during the postoperative healing period (928 days; data not shown).

2.3.3

Histological Analysis
Figure 2.3(A) shows the gross morphology of the implant site. At 9 and

18 days, devices were surrounded by fibrous and inflammatory tissue. At 28 days,
the amount of tissue was significantly reduced as the drug delivery component of
the implants was degraded and the poly(lactic-co-glycolic acid) shell collapsed
and began to disintegrate. In Figure 2.3(B), comparison of the three types of
devices shows similar appearance after 28 days. In all groups, implants had
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largely been degraded and some fibrous scar tissue was present at the surgical
site.

Sustained Release

Simvastatin Release (µM) 0

Intermittent Release

0.6

0.3

0
0

5

10
Time (Days)

Figure

2.2.

Comparison between the intermittent and the sustained

release profiles for 10-layer devices .

Figure 2.4 shows the bone-forming ability of released simvastatin acid.
Much newly formed woven bone with islands of matrix stained more intensely
with eosin and osteocytes were found on the calvarium. Furthermore, many
blood vessels were generated in and around the new bone area.
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Newly formed woven bone thickness was significantly different between
the control simvastatin acid release groups (Fig. 2.5 and 2.6). Fibrous and
inflammatory tissue was found above the newly formed bone. Intermittent release
devices stimulated 133% greater woven bone thickness (187±40 µm) compared
to control devices (80±30 µm) (p<0.05), and sustained release devices
stimulated 77.5% greater woven bone thickness (142±56 µm) (p<0.05) compared
to controls. Comparing the two release profiles, intermittent devices stimulated a
32.3% greater response than did the sustained release (p<0.05).

9 days

28 days

28 days

Control

(A)
Figure 2.3.

Sustained

Intermittent

(B)

Gross morphological state of tissues (A) around sustained

release devices at different healing times (9, 18, and28 days) and (B)
around different devices after 28 days.
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B
W
B
O

L
C

Figure 2.4.

Representative photomicrograph showing the formation of

woven bone (W), lamellar bone (L), osteocytes (O), and blood vessels (B)
above the calvarium (C).
Woven bone thickness varied from implant center to periphery, as shown
in Figure 2.7 The site directly below the device showed minimal woven thickness
(18.8-36±7.6-40 µm) compared to other locations (44-205.1±6.53-38.5 µm)
(p<0.05). Figure 2.8 shows the total area of new bone and the percentage of
more intensely stained matrix relative to total bone. Intermittent release groups
elicited 162.7% larger new bone area and sustained delivery stimulated 74.1%
more new bone area than did control implants. The percentage of intenselystained bone matrix for the intermittent (25.5%) and sustained groups (24.8%)
was higher than that for the controls (21.3%) (p<0.05). Comparing alternating
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and sustained groups, although the alternating group was slightly higher, the
difference was not statistically significant.

Control

Sustained

Intermittent

Figure 2.5.

Represenative photomicrographs comparing new bone

formation above the calvarium in all experimental groups.
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2.4

DISCUSSION

The present results demonstrate that locally released simvastatin acid
stimulated supracalvarial bone growth. Osteogenesis was enhanced by both
intermittent and sustained delivery.
All specimens showed signs of inflammatory responses up to 18 days.
Newly formed woven bone was found in controls animals implanted with blank
(drug-free) devices as well as in those in the sustained and intermittent release
groups. Inflammatory responses on bone formation are related to cytokine
mediators, which influence cells locally to change remodeling activities
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associated with appositional bone growth [113-115]. Accordingly, inflammatory
responses may be one of the main contributions to formation of new bone found
in all groups, with localized release of simvastatin acid enhancing the effects.
Even though the studies were not intended to quantitatively assess
angiogenesis, it is interesting to note that many newly formed blood vessels were
found in around the woven bone in all groups. However the simvastatin treated
groups had a higher degree of angiogenesis than control groups (data not
shown). These blood vessels likely increased blood flow in and around the
implantation site and expedited new bone formation. It was reported by Kureishi
et al. that simvastatin acid administration promotes new blood vessel growth [52].
The newly formed bone was composed of large areas of woven bone
intermixed with areas of lamellar bone. These islands were identified by their
greater organization and differential staining, with the more mature bone staining
more intensely.

It is thought that an appositional growth occurred as layers of

bone were formed over the existing calvarium, resulting in overall bone growth
[116], similar to what is observed during intramembranous ossification.

Even

though new bone thicknesses stimulated by the intermittent release devices was
highest and for the control devices was lowest, the morphology of newly formed
bone and presence of islands of lamellar bone in all three groups were
analogous.

However, the slightly higher percentage lamellar bone stimulated by

both types of drug-containing devices suggests that simvastatin acid delivery
stimulated bone formation and bone maturation.
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The present results are in accordance with previous reports of simvastatin
delivered via injection in mice. Mundy’s’ group subcutaneously injected three
different doses (1, 5, or 10 mg/kg/day, which would be 30, 150, or 300 µg/day for
a 30 g mouse) of simvastatin for 5 days, and reported increases in total bone
area of 2, 20, and 46%, respectively [1]. In other studies, treatment with low
doses of simvastatin increased cancellous bone volume and the transverse area
of fracture callus. Our release devices had alternating five or ten simvastatinloaded layers and intermittently or continuously delivered 1 µg/layer for no more
than 12 days, yet they promoted bone formation to either a 74% (sustained) to
163% (intermittent) increase in bone area.

It is thought that the present devices

would be a candidate for localized bone formation as well as or better than
subcutaneous injections.
A limited number of groups have investigated materials for localized
delivery of simvastatin [3-5,117].
methylcellulose gel [5].

Thylin et al. injected simvastatin mixed into

They reported an optimal does of 2.2 mg simvastatin

yielding up to 170% increase in calvarial thickness.

“Extensive” leakage of the

gel from the injection site was noted for some animals.

Simvastain (crushed

Zocor tablets) has also been mixed with absorbable collagen and implanted into
rabbit calvarial defects [118]. A dose of 0.5 mg simvastatin per 0.2 g collagen
sponge stimulated filling in the defects, but the kinetics of drug release were not
studied.

A reservoir system with methylcellulose gel containing 0.1-2.2 mg of

simvastatin under a biodegradable poly(lactic acid) membrane enhanced bone
formation by 45% on the rat mandible, but considerable inflammation occurred
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[3].

Although not tested in vivo, other approaches to delivering simvastatin

include incorporation in hydroxypropylmethyl cellulose, sodium carboxymethyl
cellulose, and chitosan for short term (approximately 6 hr) release [117] and
attachment to poly(lactic-co-glycolic acid) for extended retention of the drug
[119,120] . The intermittent and sustained release devices described in this paper
had approximate totals of 5 µg and 10 µg simvastatin acid, respectively, and they
stimulated 78% (sustained) to 133% (intermittent) increased bone thickness
compared to control groups.
In previous work, the drug delivery component of the implants was totally
degraded within two weeks in vitro, but the PLGA membrane used for controlling
directionality of simvastatin acid release remained in the sample solution [46].
Depending on the ratio of lactic acid to glycolic acid, PLGA degradation rates
vary from 1 to 6 month [121]. Due to the large difference in degradation times for
CAP/PF-127 and PLGA, even though the CAP/PF-127 drug release component
was entirely degraded, some degree of fibrous and inflammatory tissue
surrounded the remaining PLGA fragments after 28 days.
Diffusion of released simvastatin acid to peripheral tissues increased new
bone thickness at the edges of the calvariae. Mechanical and/or chemical effects
may have resulted in minimal bone formation directly under the devices. For
example, relative motion between implant and bone may have occurred during
daily activities of the animals, and locally concentrations of CAP/PF-127 erosion
products would have been higher directly under the devices. To achieve a more
even layer of new bone, additional space may be required directly under the
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implant. Placement of the drug delivery device in conjunction with a
biodegradable scaffold or other space-making implant could alleviate the
nonuniformity. Alternatively or in addition, the implant may be protected from
movement immediately following placement.

2.5

CONCLUSION

Using a multilayering method, devices for localized delivery of CAP/PF-127
were fabricated. Alternating release devices showed five discrete peaks, while
sustained release devices showed zero-order release for approximately ten days.
Based on our experimental results, local delivery of simvastatin acid with either
sustained or intermittent release profiles stimulated formation of new bone in vivo.
Furthermore, the intermittent devices were more effective than sustained devices,
while requiring only one half the amount of drug.

Copyright © Ju Hyeong Jeon 2007
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Chapter Three

INTERMITTENT RELEASE OF PARATHYROID HORMONE (1-34)
BIODEGRADABLE DEVICE ENHANCES OSTEOBLASTIC ACTIVITIES
3.1

INTRODUCTION

Parathyroid hormone (PTH) is well known for its role in calcium
homeostasis. The N-terminal fragment comprising the first 34 amino acids,
PTH(1-34), has biological activity comparable to the whole molecule. It has been
reported that daily injections of low doses of PTH or PTH(1-34) stimulate bone
formation and increase bone mass in humans and animals [7,12,14,60-63]. Many
in vivo studies have been conducted to explain the anabolic effect of PTH or
PTH(1-34) on bone formation, and experiments with intermittent infusion and
injection of PTH(1-34) have shown increased bone mass [26]. It is thought that
PTH increases bone formation by decreasing the apoptosis of osteoblasts [11],
whereas continuous administration of PTH or PTH(1-34) result in decreased
bone mass [15,64,122]. These results imply that the effects of PTH on bone cells
vary with cell type and experimental conditions, such as intermittent or
continuous administration [10]. Many in vitro studies have been conducted to
determine PTH effects on bone. From the results, it is clear that PTH enhances
proliferation of primary osteoblastic cells from humans and animals [65,66]. In
addition, PTH exerts diverse effects on osteoblast differentiation depending on
differentiation stage [123,124].
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To mimic the effect of injections, devices need to provide intermittent
release profiles. We previously investigated an association polymer system
based on blends of cellulose acetate phthalate (CAP), which is a well known
enteric coating material in the pharmaceutical industry, and a nonionic surfactant,
Pluronic F127 (PF-127), which is used for stabilizing proteins and peptides during
lyophilization. The CAP/PF-127 polymer system is useful for programmed drug
delivery, with the rate, duration, and amount of released drug controlled by
thickness, blending ratio, and number of layers [16,47].
The objective was to develop devices for intermittent release of PTH(1-34)
and to determine the effects of PTH(1-34) released with different profiles on
osteoblastic cellular activity. Our hypothesis was that the mode of local PTH(134) release affects osteoblastic activity. To verify this hypothesis, in this study,
devices for intermittent delivery of PTH(1-34) were developed, and it was
demonstrated that the cellular effects of PTH(1-34) on osteoblastic proliferation
and differentiation were dependent on mode of administration.

3.2
3.2.1

MATERIALS AND METHODS

CAP/PF-127 Microspheres and Release Devices
PTH(1-34) (Bachem, Torrance, CA) was labeled with Alexa Fluor 350

Carboxylic acid, succinimidyl ester (Invitrogen, Eugene, OR) to enable
measurement of the released amount. CAP (Fluka, Buchs, Switzerland) and PF127 (Sigma, St Louis, MO) microspheres were made by a water-acetone-oilwater (W/A/O/W) triple emulsion process. CAP and PF-127 polymer blend (7:3
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weight fraction of CAP and PF-127) was dissolved in acetone. To this acetone
solution, phosphate-buffered saline (PBS), pH 7.4, with 0 or 250 μg/ml of CB
were added and then homogenized into corn oil and sonicated for 20 seconds.
The CAP/PF-127 suspension and 5% Triton X-100 solution were added to
deionized water and then stirred to harden the microspheres for 5 minutes.
Following collection, microspheres were washed, filtered, and lyophilized
overnight.
Release devices were made using a pressure-sintering process. Fifteen to
20 mg of UV-sterilized microspheres containing PTH (1-34) were placed in the
wells of a Delrin mold (diameter, 6.2 mm; depth, 20 mm) and consolidated by
applying 20 MPa pressure for 5 sec. Next, for intermittent devices, blank
microspheres were added on top of the first layer, and pressure was reapplied.
By repeating this process, ten-layer devices were prepared. For sustained
release devices, all layers were composed of microspheres containing PTH(1-34).
To provide directional control of drug release, the bottom and sides of the devices
were coated three times with 10% poly(lactic-co-glycolic acid) (75:25, Mw~75
kDa; Alkermes, Cincinnati, OH) solution in methylene chloride.
3.2.2

In Vitro Release
Devices were immersed in 5 ml PBS, pH 7.4, and incubated at 37ºC.

One ml of supernatant was collected and the remaining PBS replaced daily. To
allow quantification of released PTH(1-34), CAP was precipitated from the 1 ml of
supernatant by treatment with 50 μl of 0.1 M hydrochloric acid. Acid-treated
supernatants were then centrifuged at 1000 rpm for 5 minutes. Solutions were
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placed into 96-well assay plates, along with labeled PTH(1-34) standards made
by serial diluting from a 100 ng/ml stock solution. The concentrations of labeled
PTH(1-34) were determined fluorometrically using a SpectraMAX Gemini XS ®
(λex=346 nm, λem=442 nm). In order to investigate pH changes, devices were
immersed in 5 to 15 ml PBS at 37ºC, and the pH was measured each day.
3.2.3

Cell Culture
MC3T3-E1 preosteoblastic cells (CRL-2593; ATCC, Manassas, VA) were

seeded at a density of 15,000/cm2 into 24-well tissue culture plates in α-Minimum
Essential Medium (MEM) containing 10% fetal bovine serum (GIBCO/Invitrogen,
Carlsbad, CA), 50 µg/ml ascorbic acid (Sigma), 5 mM ß-glycerophosphate
(Sigma),and antibiotics (penicillin G and streptomycin GIBCO ), and 0-5 ng/ml
PTH(1-34). In sustained release cultures, one set of cells was constantly
exposed to various PTH(1-34) at a fixed concentration.

In intermittent release

cultures, another set was exposed to alternating concentrations. In control
cultures, medium was changed on the same schedule, but it did not contain
PTH(1-34).
3.2.4

In Vitro Bioassays
After 3, 7, 10, and 14 days of culture, cells were harvested and then lysed

by sonication in high salt solution (0.05M NaH2PO4, 2M NaCl, and 2mM EDTA).
DNA standards were prepared by serial diluting calf thymus DNA in the high salt
solution. Hoechst 33258 (final concentration, 0.5 µg/ml; Sigma) was added to
DNA standards and samples and allowed to react in the dark for 10 minutes [125].
The amount of DNA in the samples was determined by measuring fluorescence
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(λex=356 nm, λem=458 nm).
To measure alkaline phosphatase (AP) activity, lysed cell samples were
incubated with substrate solution prepared by dissolving 10 mM of Sigma 104
phosphatase substrate in Sigma 221 alkaline buffer solution. After 30 minutes,
0.25 N NaOH was added to each well to immediately stop enzyme activity.
Absorbance at 410 nm was measured with an MR5000 microplate reader
(Dynatech Laboratories, Chantilly, VA), and the amount of substrate cleaved was
determined using ε=1.7x104 M-1cm-1. Activity was expressed as nM of substrate
cleaved per minute and then normalized by DNA content.
For measuring osteocalcin (OCN) secretion, conditioned medium collected
from cultures samples was assayed using an EIA kit (Biomedical Technologies,
Stoughton, MA) following the manufacturer’s protocol.

Concentrations were

determined from a standard curve constructed using mouse OCN.
3.2.5

Statistical Analysis
Results (mean and standard deviation) were calculated from at least six

replicate samples. One-way analysis of variance (ANOVA) was conducted using
the computer application InStat (Graphpad Software, San Diego, CA). Post-hoc
comparisons were made using the Tukey-Kramer test when the p-value was
significant (p<0.05).

3.3 RESULTS
3.3.1 Release Profiles and Sample pH
The CAP/PF-127 polymer degraded by erosion at the one surface
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exposed to the aqueous environment. In Figure 3.1, device weight and thickness
were decreased linearly at the rate of 11.5 mg/day-15.4 mg/day over the period
of the experiments, as expected from zero-order kinetics.
Intermittent release profiles were achieved by alternately layering PTH(1-34)loaded microspheres and blank (unloaded) microspheres. Figure 3.2 shows both
intermittent and sustained release profiles for 10-layer devices. With sustained
release devices, the amount of released PTH(1-34) gradually increased over the
first 3 days, and afterward the amount of delivered PTH(1-34) remained relatively
constant and showed a zero-order release profile. In contrast, intermittent
release devices provided five discrete peaks, each separated by 2-3 days. Figure
3.3 shows cumulative release of PTH(1-34) from intermittent and sustained
release devices. Sustained release devices were composed of 10 PTH(1-34)loaded layers, but intermittent release devices were fabricated with 5 PTH(1-34)loaded and 5 blank layers. Consequently, the total amount of PTH(1-34) released
from intermittent release devices was close to half that from sustained release
devices (p<0.05).
Figure 3.4 shows the pH in intermittent release samples at each day. All
devices in various amounts of PBS were degraded in 13 days, as also shown in
the previous figure. When devices were immersed in 5, 10, and 15 ml of PBS,
the ranges of pH of samples were 6.64 - 6.88, 6.76 -6.91 and 7.05-7.24,
respectively. For samples incubated in 10 and 15 ml PBS, pH was more stable
through out the degradation period compared to those incubated in 5 ml, but at
day 13, pH was 0.15-0.19 lower than any other period (p<0.05).
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Figure 3.1. Device thickness and weight changes during degradation of
10-layer release devices.

3.3.2

Effect of Alternating or Constant Concentrations of PTH(1-34) on

Osteoblastic Cells
In order to determine proper levels of PTH(1-34) release from the
devices and to investigate effects of concentration, and mode of exposure to
PTH(1-34), cell responses were investigated. Results for DNA contents in
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MC3T3-E1 cultures exposed to intermittent or sustained delivery of PTH(1-34)
are shown in Figure 3.5. At day 3, DNA contents in osteoblast cultures treated
with both sustained and alternating concentrations of PTH(1-34) were 64-86%
higher than in controls (p<0.05). At day 7, all groups except the sustained 500
pg/ml showed their highest DNA contents (p<0.05) during culture, however levels
in the 5 ng/ml alternating group were slightly higher than the others. At day 10, all
groups except the 500 pg/ml sustained showed a slight decrease in DNA content

Intermittent

PTH Release (ng) 0

60

Sustained

40
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0
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15

Time (Days)
Figure 3.2. Instantaneous release of PTH(1-34) from 10-layer intermittent
and sustained release devices.
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Figure 3.4. Daily pH in sample solution during degradation of 10-layer
devices.
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, with a decrease for the 5 ng/ml sustained group. At day 14, both alternating and
sustained 5 ng/ml groups had similar DNA contents as 10 days, while other
groups had decreased levels.
AP activity in PTH(1-34)-treated cultures is shown in Figure 3.6. At day 3,
AP activity was 50-106% higher in PTH(1-34)-treated cultures compared to
controls (p<0.05). At day 7, all groups showed increased AP activity except 500
pg/ml sustained. At day 10, all groups showed their highest AP activity, while at
day 14, all groups showed decreased AP activity. AP activity in cultures exposed
to 5 ng/ml alternating PTH(1-34) had the largest decrease compared to other
groups. Cells treated with alternating levels of 5 ng/ml PTH(1-34) showed the
highest overall activity at day 10.
6
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Figure

3.5.

DNA content in cultures exposed to sustained and

intermittent PTH(1-34).
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In Figure 3.7, all experimental groups showed increased OCN contents
compared to control groups (p<0.05). At day 1, there was no significant
difference in OCN secretion between sustained and alternating groups in the
same concentration, but from days 2 to 10, cultures treated with alternating levels
of PTH(1-34) stimulated significantly greater (14-267%) osteocalcin secretion
compared to cells constantly treated with the same concentration (p<0.05).
Cultures exposed to alternating PTH(1-34) showed increasing OCN secretion
through the period of culture (10 days), but OCN secretion in cultures treated
with constant concentrations of PTH(1-34) plateaued earlier (by 6 days).
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Figure 3.6. AP activity in cultures exposed to sustained and intermittent
PTH(1-34).
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Figure 3.7. Osteocalcin secretion for osteoblasts exposed to sustained
and intermittent PTH(1-34). ??did you check statistics for sus groups at 4
and 6 days??

3.4 DISCUSSION
Blends of CAP and PF-127 form an association polymer that undergoes
surface erosion and shows zero-order release [16,46]. A number of ether sites in
PF-127 and carboxylic acid groups in CAP form hydrogen bonds. When these
hydrogen bonds are exposed to aqueous solution, carboxyl groups start to
deprotonate, and the material degrades. The deprotonation makes the
surrounding solution acidic. Acidic conditions can have adverse effects on bone
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and bone cells. Decreasing pH reduces expression of ALP and OCN in bone
marrow stromal cells [126]. In particular, pH below 6.6 caused two- to three-fold
decreased ALP expression. Another group showed that acidic conditions upregulates PTH/PTHrP receptors in osteoblast-like cells [127]. In order to prevent
local acidosis, and reduced ALP and OCN expression, pH at the site of a
degrading CAP/PF-127 implant should be kept above 6.6 [128]. Our samples had
slightly acidic pH, down to 6.64 when incubated in the smallest volume of PBS. In
larger volumes, release supernatants were nearly neutral. Continuous clearance
of degradation products in vivo would be expected to minimize pH changes.
Preliminary studies in a rat model did not show adverse effects.
By modifying surface area, layer thickness, and alternatingly loading
layers in the devices, PTH(1-34) release can be controlled. Unlike the cumulative
release profile of sustained release devices, alternating devices showed
relatively flatter regions, which reflect erosion of unloaded layers. Directional
control of delivery was provided by coating with a more hydrophobic
biodegradable polymer, in this case poly(lactide-co-glycolide). Thus, only one
surface was exposed to PBS. Theoretically, the lowest points in the intermittent
release profiles should have reached zero PTH(1-34) because the blank layers
did not contain peptide. However, low but measurable concentrations were
detected. It is believed that when fabricating the multilayered devices, some
microspheres adjacent to loaded and blank layers became intermingled under
pressure and sampling interval also affect to the result. Our devices were even
10 layer device with 13 day of degradation time. Ideally, sampling interval should
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have been 1.3 day or more frequent sampling such as 3 times or 4 times a day.
By 1 day sampling interval, we can closely calculate the trend of release profile of
the devices but somewhat difficult to figure out exact release profile.
The plasma half life of intact PTH(1–34) is less than 11 min [36]. The fast
metabolic degradation of PTH requires multiple administrations of PTH
necessary to keep the effective concentration in the plasma [78]. Normally, the
physiological PTH level in plasma is 500 +/- 30 pg/ml, and there is no significant
difference according to age or sex [129]. Our work provided a maximum 20 times
higher PTH(1-34) concentration. The release devices were not intended for
systemic delivery but for local delivery. Encapsulated PTH(1-34) can be protected
from degradation factors, such as oxidization, water, and enzymes, until released
from devices and then it is available to travel a short distance to the target area.
Consequently, local delivery of PTH(1-34) enables enhancement of osteoblastic
activity and bone formation with smaller amounts of PTH(1-34) compared to
systemic delivery of PTH(1-34).
Many approaches to intermittent PTH delivery have been investigated,
such as injections, oral dosing, pulmonary inhalation, and transdermal delivery
[35-41]. Most of these studies are focusing on systemic delivery for treatment of
osteoporosis, whereas relatively few studies have looked at local delivery of
PTH(1-34) for repair of focal bone defects. Pulmonary inhalation of 18-20 µg
PTH(1-34) gave a plasma concentration of approximately 45 ng/ml, but the
duration was less than 120 min [41]. Consequently, continuous inhalations were
required

for

achieving

and

maintaining
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effective

concentrations.

PLGA

microspheres incorporating PTH(1-34) were developed for local delivery [78].
Although the microspheres sustained delivery of the peptide for more than 11
weeks, it is difficult to achieve pulsatile release with this system. Recently, Liu
et al. described a system for pulsatile delivery of PTH(1-34) [35]. PTH(134)/alginate films were alternated with polyanhydride layers inside a PLLA
container.

Release

profiles

showed

4

sharp

peaks,

with

PTH(1-34)

concentrations of 40-65 ng/mL, over a period of 4 days. Our devices provided 5
discrete peaks with PTH(1-34) concentrations of 21-41 ng/ml for 12 days.
Comparing alternating and sustained exposure to the same PTH(1-34)
concentration, intermittent exposure stimulated higher osteoblastic activity. This
could be expected, because continuous exposure down-regulates expression of
its receptor in target cells [130,131]. PTH at physiological concentration is a
potent suppressor of osteoblast differentiation; it is thought that PTH prevents
differentiation of preosteoblasts into osteoblasts [132]. The results in these
studies correspond to our bioactivity results.

3.5 CONCLUSION
This work describes devices for local intermittent, delivery of PTH(1-34)
without injection. By alternatingly loading microspheres with and without PTH(134), intermittent release of PTH(1-34) was achieved using the association
polymer system of CAP and PF-127. A slightly acidic condition that comes from
erosion of the polymer may up-regulate expression of PTH receptors in cells. In
vitro bioactivity experiments showed that either intermittently or sustained
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exposing osteoblastic cells to PTH(1-34) enhanced their activity, but intermittent
exposure resulted in enhanced cellular activity. These devices warrant further
development for enhancing localized formation of bone.

Copyright © Ju Hyeong Jeon 2007
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Chapter Four

ALTERNATING RELEASE OF DIFFERENT BIOACTIVE MOLECULES

4.1 INTRODUCTION
Controlled

release

technology

enables

delivery

of

a

variety

of

biomolecules at the proper time, in the appropriate amount, and to the desired
site. Most commonly, investigators seek to release one drug at constant
concentrations for extended periods.
undesirable.

However, such zero-order kinetics can be

For example, parathyroid hormone (1-34) (PTH(1-34)) can have

either anabolic or catabolic effects on bone, depending on the mode of delivery.
Daily administration of low doses of PTH stimulates bone formation and
increases bone mass in humans and animals in vivo [7,12,14], and it enhances
proliferation of primary osteoblastic cells [61,62] and diverse effects on osteoblast
differentiation depending on differentiation stage [14,63]. In contrast, continuous
administration of PTH has a catabolic effect

[8,9,15,64].

Simvastatin (Sim), a member of the statin family of drugs know for
lowering serum cholesterol, also has been reported to stimulate bone formation
[1]. According to Mundy’s group, treatment of cell cultures with Sim induced
expression of bone morphogenetic protein 2 (BMP-2), and daily subcutaneous
injections of Sim stimulated bone formation on the calvaria of mice. Other studies
showed that oral dosing with simvastatin increased cancellous bone volume in
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rats [51], and it also increased transverse area of fracture callus as well as
mechanical properties compared to controls [2].
Regeneration of bony defects can be complex and involves sequential
cascades of events [80]. Furthermore, these sites may face the threat of
microbial infection, especially compound fractures and periodontal lesions.
Infections in bony sites can be difficult to treat. Treatment may require multiple
surgeries, prolonged antibiotic treatment, and long-term complications. Therefore,
every effort is required to prevent this problem with early treatment [81]. Cecropin
B (CB) is a naturally occurring cationic, amphipathic peptide derived from moths
that has broad spectrum activity against not only certain gram-positive bacteria
but also gram-negative bacteria, fungi, and parasites [84-86]. CB has an EC50
(half maximal effective concentration) from 4 to 80 µg/ml, depending on the
microorganism [86,90,91].
Currently, therapies for tissue regeneration in the body mainly rely on the
delivery of single biomolecules. Microspheres, nanospheres, and porous
scaffolds comprised of numerous polymers, such as polylactides, polyglycolides,
poly(lactide-co-glycolides), polyanhydrides, and polyorthoesters, have been
developed for delivery of one biomolecule at a time [21-24,41,78,133,134], but
few studies have been consulted with multiple biomolecules [92,93,135,136].
However, multiple signals are required to drive the regeneration process to
completion in a timely and efficient manner, and consequently the success of
current efforts releasing a single biomolecule to the defect site may be limited
[92]. An approach to overcome limitations of single molecule delivery is release

66

of multiple molecules with distinct kinetics to trigger the desired tissue responses.
In previous studies, we developed a controlled release system based on
blends of cellulose acetate phthalate (CAP) and Pluronic F-127 (PF-127) for
intermittent release of small and large biomolecules [16,46]. The CAP/PF-127
polymer system can be used for programmed drug delivery, with the rate,
duration, and amount of released drug controlled by blending ratio, number of
layers, and thickness [16,46,47]. The objective of this research was to further
develop the CAP/PF-127 system for alternating delivery of multiple biomolecules
and to investigate effects on osteoblastic cells.

4.2 MATERIALS AND METHODS
4.2.1 CAP/PF-127 Microspheres
Cecropin-B (Anaspec, San Jose, CA) and PTH(1-34) (Bachem Torrance,
CA) were labeled with Alexa Fluor 350 Carboxylic acid, succinimidyl ester
(Invitrogen, Eugene, OR) and Alexa Fluor 488 Carboxylic acid, succinimidyl ester
(Invitrogen), respectively, to enable measurement of the released amounts. CAP
(Fluka, Buchs, Switzerland) and PF-127 (Sigma, St Louis, MO) microspheres
were made by a water-acetone-oil-water (W/A/O/W) triple emulsion process.
CAP and PF-127 polymer blend (7:3 weight fraction of CAP to PF-127) was
dissolved in acetone. One ml of phosphate-buffered saline (PBS), pH 7.4,
containing CB (250 or 500 μg/ml), PTH(1-34) (50 or 100 μg/ml), or Sim (420 or
840 μg/ml; Aldrich, Milwaukee, WI) was added to the polymer solution,
homogenized into corn oil, and then sonicated for 20 seconds. The CAP/PF-127
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suspension and 5% Triton X-100 solution were added to deionized water and
then stirred for 5 minutes to harden the microspheres. Following collection,
microspheres were washed, filtered, and lyophilized overnight.
4.2.2 Release Devices
Release devices were fabricated using a pressure-sintering process and
consolidated in acetone vapor. The first layer of CB/Sim and CB/PTH devices
was made with 20 mg of mixed UV-sterilized microspheres (10 mg of each type).
They were then placed in the wells of a Delrin mold (diameter, 6.2 mm; depth, 20
mm) and consolidated by applying 20 MPa pressure for 5 sec. Next,
microspheres containing only CB were added on top of the first layer, and
pressure was reapplied. The third layer consisted of only Sim-containing
microspheres for CB/Sim release devices or PTH-loaded microspheres for
CB/PTH devices. Ten-layer devices were made by repeatedly alternating CB and
Sim or PTH(1-34). Sim/PTH release devices were made by alternating layers of
PTH- and Sim-containing microspheres.
Figure 4.1 depicts the design of the three devices. To provide directional
control of drug release, the bottom and sides of the devices were coated three
times with 10% poly(lactic-co-glycolic acid) (75:25, Mw~75 kDa; Alkermes,
Cincinnati, OH) solution in methylene chloride.
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(A)

CB
Sim or PTH
CB
Sim or PTH
CB
Sim or PTH
CB
Sim or PTH
CB
CB + Sim or PTH

Directional Release

(B)

Impermeable
PLGA Coating

PTH
Sim
PTH
Sim
PTH
Sim
PTH
Sim
PTH
Sim

Directional Release

Figure 4.1. Schematic representation of (A) CB/Sim and CB/PTH devices
and (B) Sim/PTH devices.

4.2.3 Characterization of Microspheres
Drug content was determined by dissolving 100 mg of microspheres in 5
ml of PBS followed by precipitation of CAP in the solution with 50 μl of 0.1 M
hydrochloric acid. After centrifugation at 190 G-force (g) for 5 minutes, samples
were placed into 96-well assay plates, along with solutions of Sim, fluorophorelabeled CB, and fluorophore-labeled PTH. Each standard was made by serial
diluting from a known stock solution. The concentrations of released Sim, CB,
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and PTH(1-34) were determined fluorometrically using a SpectraMAX Gemini
XS (PTH(1-34): λex=346 nm, λem=442 nm; CB: λex=495 nm, λem=519 nm; and
Sim: λex=390 nm, λem=413 nm). Mean diameter of microspheres was measured
using a Partica LA-950 Laser Diffraction Particle Size Analyzer.
4.2.4 In Vitro Release
Samples were immersed in 5 ml of PBS, pH 7.4, and incubated at 37ºC.
Supernatant was collected and replaced daily to maintain a constant volume. To
allow quantification of released biomolecules, CAP was precipitated from the
supernatant by treatment with 50 μl of 0.1 M hydrochloric acid, and fluorescence
was measured as described in the previous section. In order to investigate pH
changes, devices were immersed in 15 ml PBS at 37ºC, and the pH was
measured each day.
4.2.5 Cell Culture
MC3T3-E1 preosteoblastic cells (CRL-2593; ATCC, Manasas, VA) were
seeded at a density of 15,000/cm2 into 24-well tissue culture plates in α-Minimum
Essential Medium (MEM) containing 10% fetal bovine serum (GIBCO/Invitrogen,
Carlsbad, CA), 50 µg/ml ascorbic acid (Sigma), 5 mM ß-glycerophosphate
(Sigma), 1 μg/ml CB, 100 pM-1 µM Sim, and 500 pg/ml-50 ng/ml PTH(1-34). In
CB/Sim, CB/PTH, and Sim/PTH release cultures, one set of cells was
alternatingly exposed to CB and Sim, CB and PTH, and Sim and PTH(1-34),
respectively. In control cultures, medium was changed on the same schedule, but
it did not contain biomolecules.

70

4.2.6 DNA and AP Assays
After 3, 7, 10, and 14 days of culture, cells were harvested and then lysed
by sonication in high salt solution (0.05M NaH2PO4, 2M NaCl, and 2mM EDTA).
DNA standards were prepared by serial diluting calf thymus DNA in the high salt
solution. Hoechst 33258 (final concentration, 0.5 µg/ml; Sigma) was added to
DNA standards and samples and allowed to react in the dark for 10 minutes [98].
DNA content of the lysates was quantified by measuring fluorescence (λex=356
nm, λem=458 nm).
Alkaline phosphatase (AP) activity was determined by a colorimetric assay.
Lysates were incubated with substrate solution prepared by dissolving 10 mM of
Sigma 104 phosphatase substrate in Sigma 221 alkaline buffer solution. After 30
minutes, 0.25 N NaOH was added to each well to immediately stop enzyme
activity. Absorbance at 410 nm was measured with an MR5000 microplate reader
(Dynatech Laboratories, Chantilly, VA), and the amount of substrate cleaved was
determined using ε=1.7x104 M-1cm-1. Activity was expressed as nM of substrate
cleaved per minute and then normalized by DNA content.
4.2.7 Statistical Analysis
All data were analyzed by analysis of variance (ANOVA) using the
computer application InStat (Graphpad Software, San Diego, CA). Post-hoc
comparisons were made using the Tukey-Kramer Comparison Test when the pvalue was significant (p<0.05).
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4.3 RESULTS
4.3.1 Characterization of Microspheres
Drug content and encapsulation efficiency of three different biomoleculecontaining microspheres are shown in Table 1. Drug content per g polymer and
encapsulation efficiencies of CB, Sim, and PTH(1-34) microspheres were 11.2,
85.1, and 111 μg and 53.1(p<0.05), 47.2(p<0.05), and 39%(p<0.05), respectively.
As shown in Table 2, the mean size of blank, CB-, Sim-, and PTH(1-34)-loaded
microspheres was 104, 161, 141, and 159 μm, respectively. Compared to blank
microspheres, CB, Sim, and PTH(1-34) microspheres were 56.3% (p<0.05),
37.3% (p<0.05), and 54.4%(p<0.05)

respectively, larger in mean size.

Table 4.1. Drug content and encapsulation efficiency for the three types
of microspheres.
Initial

Drug

M.S.

Total Drug

Drug Content

CAP/PF-127

Added

Harvested (g)

Content (μg) /

per g polymer

/ Yield (%)

*

E.E. (%)

(μg)

1.654±0.124 /

24.6±9.1 /

82.7 ±7.5

39±36.9

1.563 ±0.215

132.8±17.5 /

/ 78.2 ±13.7

53.1±13.1

1.788 ±0.298

198.6±18.7 /

/ 89.4 ±16.7

47.2±9.4

(g)

(μg)

PTH

1.4/0.6 = 2

50

Cecropin B

1.4/0.6 = 2

250

Simvastatin

1.4/0.6 = 2

420

* encapsulation efficiency. Data are the mean of four replicates
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11.2

85.12

111.1

Table 4.2. Sizes of the three types of microspheres.
Blank

Cecropin B

PTH

Simvastatin

Mean Size (μm)

103.92

161.16

159.08

141.18

Median Size (μm)

117.72

168.87

184.34

123.245

Std. Dev (μm)

67.894

113.31

90.161

89.848

Refractive Indices : D.I. water, 1.333; CAP, 1.475. Data are the mean of four replicates

4.3.2 Sample pH and Release Profiles
Figure 4.2 shows the pH at each day for the three different devices
developed. CB/PTH devices were degraded in 15 days, and CB/Sim and
Sim/PTH devices degraded in 16 days. Solution pH decreased from 7.4 to 6.967.04 over the first 1-2 days and then was stable until the last time points, when
the devices fully eroded. The ranges of pH for CB/Sim, CB/PTH, and Sim/PTH
devices were 6.95-7.23, 6.97-7.37 and 6.96-7.28, respectively. Alternating
release profiles were achieved by sequentially layering microspheres loaded with
different biomolecules.
Figure 4.3 shows release profiles for devices designed to alternately
release CB and PTH(1-34). Overall, five discrete release peaks were observed
each for CB and PTH(1-34). To prevent early stage infection, CB release was
maintained for three days at the beginning. During the release period, CB
showed uniform peak concentrations (0.68-0.94 µg/ml), and PTH(1-34) also had
relatively even maximum release (59-78 ng/ml), except for the last peak when
integrity of the devices was lost. Figure 4.4 shows release characteristics of
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devices alternately fabricated with CB and Sim. Again, prolonged CB release was
observed over the first three days followed by five discrete release peaks for
each component over a 15 day period. The range of concentration of CB and
Sim are 0.76-0.95 µg/ml and 1.26 -1.56 µM,
respectively.

8
7.8

Sim/PTH

CB/PTH

CB/Sim

7.6
7.4
pH

7.2
7
6.8
6.6
6.4
6.2
6
0

Figure

4.2.

5

10
Time (Days)

15

pH in sample solutions during degradation of 10-layer

devices. Data are the mean of six replicates. Error bars, which ranged from
11-28% of the mean, are not shown to prevent obscuring the curves.
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Figure 4.5 shows results for devices alternately loaded with Sim and
PTH(1-34). Each release profile had 5 distinguishable peaks. In the Sim release
profile, the first two peaks were sharp and high (1.58-1.65 µM), but the next two
were relatively broad and gave lower concentrations (0.97-1.12 µM) than the first
two. PTH(1-34) peaks showed relatively even release for the first four peaks
(77.2-83.16 ng/ml), but a lower peak was observed for the late one (54.1 ng/ml).

PTH
Cecropin-B

80

1.2
1
0.8

60

0.6
40

0.4

20

0.2

0

Cecropin-B Release (μg/ml) 0

PTH Release (ng/ml) 0

100

0
0

5

10

Time (Days)
Figure 4.3. Release profile from 10-layered CB/PTH devices. Data are the
mean of six replicates. Error bars, which ranged from 11-31% of the mean,
are not shown to prevent obscuring the curves.
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4.3.3 Effect of Combined Delivery of Biomolecules on Osteoblastic Cells
In Figure 4.6 a, DNA contents in all MC3T3-E1 cultures increased until the
seventh day and then showed relatively unchanging levels. Cells exposed to 1
µg/ml CB with 10 nM Sim showed higher DNA content (5.64 µg/ml) than any
other group (p<0.05). AP activity in all groups increased through the tenth day
and then decreased, except for the 1 µM Sim group (Figure 4.6 b). As was
observed for DNA content, the 10 nM Sim group had higher AP activity than any
other group (p<0.05). Unlike DNA content, however, AP activity was higher for
the 1 µM Sim group compared to controls (p<0.05).

1.2

Simvastatin
Cecropin-B

1.75

1

1.5
0.8

1.25
1

0.6

0.75

0.4

0.5
0.2

0.25
0

Cecropin-B Release (μg/ml)0

Simvastatin Release (μM) 0

2

0
0

5

10

15

Time (Days)
Figure 4.4. Release profile from 10-layered CB/Sim devices. Data are the
mean of six replicates. Error bars, which ranged from 23-34% of the mean,
are not shown to prevent obscuring the curves.
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As shown in Figure 4.7 a, all CB and PTH(1-34) treatment groups had
higher amounts of DNA (2.99-7.06 µg/ml) than did the control group (1.78- 3.37
µg/ml) (p<0.05). Although not significantly different, cultures treated with 1 µg/ml
CB and 5 ng/ml PTH(1-34) showed slightly higher DNA content until day 10. As
seen for DNA contents, all CB and PTH(1-34) treatment groups had higher AP
activity (Figure 4.7 b) (0.26-0.4

nM/min/µg/DNA) than did the control group

(0.11-0.15 nM/min/µg/DNA)(p<0.05). All groups increased through the tenth day
and then decreased slightly.

PTH
Simvastatin

80

1.75
1.5
1.25

60

1

40

0.75
0.5

20

0.25

0

Simvastatin Release (μM) 0

PTH Release (ng/ml) 0

100

0
0

5

10

15

Time (Days)
Figure

4.5.

Release profile from 10-layered Sim/PTH devices. Data are

the mean of six replicates. Error bars, which ranged from 7-22% of the
mean, are not shown to prevent obscuring the curves.
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Control
CB (1 µg/ml)/Sim (100 pM)
CB (1 µg/ml)/Sim (10 nM)
CB (1 µg/ml)/Sim (1 µM)
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DNA (µg/ml)
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CB (1 µg/ml)/Sim (100 pM)
CB (1 µg/ml)/Sim (10 nM)
CB (1 µg/ml)/Sim (1 µM)
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Figure 4.6 (a) DNA content and (b) AP activity in cultures exposed to
alternating CB and Sim.
Control
Sim (10 nM)/PTH (500 pg/ml)
Sim (10 nM)/PTH (5 ng/ml)
Sim (1 µM)/PTH (500 pg/ml)
Sim (1 µM)/PTH (5 ng/ml)

15

AP (nM/min/µg/DNA)

DNA (µg/ml)

12.5

Control
Sim (10 nM)/PTH (500 pg/ml)
Sim (10 nM)/PTH (5 ng/ml)
Sim (1 µM)/PTH (500 pg/ml)
Sim (1 µM)/PTH (5 ng/ml)

1
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Figure 4.7. (a) DNA content and (b) AP activity in cultures exposed to
alternating CB and PTH.
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In cultures exposed to alternating Sim and PTH(1-34), DNA contents
mainly depended on Sim concentration (Figure 4.8 a). DNA contents for cells
treated with 1 µM Sim were slightly higher than controls, whereas treatment with
10 nM Sim resulted in 163-259% higher amounts of DNA than the controls
(p<0.05). Furthermore, these two groups (10 nM Sim plus either 500 pg/ml or 5
ng/ml PTH(1-34)) showed 39.8-101% and 14.6-40.3% higher DNA content than
CB/Sim and CB/PTH groups, respectively (p<0.05). Alternating Sim and PTH
cultures showed higher AP activity than did the control groups (Figure 4.8 b)
(p<0.05). Furthermore, even 1 µM Sim treatment stimulated higher AP activity
than in control groups throughout the two week experiments.

Control
CB (1 µg/ml)/PTH (500 pg/ml)
CB (1 µg/ml)/PTH (5 ng/ml)
CB (1 µg/ml)/ PTH (50 ng/ml)

AP (nM/min/µg/DNA)

DNA (µg/ml)

10

Control
CB (1 µg/ml)/PTH (500 pg/ml)
CB (1 µg/ml)/PTH (5 ng/ml)
CB (1 µg/ml)/ PTH (50 ng/ml)

0.75

7.5

5

2.5

0.5

0.25

0

0
3

Time (Days)

7
10
Time (Days)

(a)

(b)

7

10

3

14

14

Figure 4.8. (a) DNA content and (b) AP activity in cultures exposed to
alternating Sim and PTH.

79

4.4 DISCUSSION
The

present

study

demonstrates

alternating

delivery

of

multiple

biomolecules and shows that such alternating concentrations increase
proliferation and early osteoblastic activity, which is critical to enhancing bone
formation. The devices were based on reports of intermittent delivery of Sim and
PTH(1-34) both promoting osteoblastic

responses

and

bone

formation

[1,3,15,37,51,66,137]. The erodible polymeric devices, developed to allow
intermittent release of a single molecule, alternating release of different
molecules, or sequential release of multiple molecules, may offer a powerful
approach in bone regeneration as well as in other medical therapies that involve
multiple biological cascades.
Drug loading and encapsulation efficiency are affected by volume of
organic solvent used in dissolving the polymer [138,139] and the initial drug
concentration. The smaller volume of organic solvent in the system promotes
precipitation of polymer. Drug loading increases with decreasing organic solvent
volume and with increasing drug concentration. The size of CAP/PF-127
microspheres used for the release devices can be controlled by modifying the
emulsification process, such as by altering agitation velocity, time, temperature,
and the parameters that influence the kinematic viscosity type, including
concentration of polymer and emulsifier [140]. In our experiments, microsphere
sizes ranged from 104 to 161 μm. It is thought that the differences of
homogenization speed, water phase temperature, and types of drug are main
reasons.
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Blends of CAP, which is a well known enteric coating material in the
pharmaceutical industry, and a nonionic surfactant, PF-127, which is used for
stabilizing proteins and peptides, form an association polymer that undergoes
surface erosion and shows zero-order release [16,46]. A number of ether sites in
PF-127 and carboxylic acid groups in CAP form hydrogen bonds. When exposed
to PBS, carboxyl groups on CAP become deprotonated, and hydrogen bonds
with ether groups in PF-127 are consequently lost, resulting in surface erosion of
the material.
When CAP is dissolved in aqueous solution, deprotonation results in
locally decreased pH. Measurement of pH showed only slight acidification below
PBS’s initial pH of 7.4. Supernatants remained close to neutral, with the lowest
pH of just 6.95 occurring at the last time point sampled when the material was
finally completely eroded. Disthabanchong et al. reported that a slightly acidic
condition (pH 7.1) up-regulated PTH/PTHrP receptors and increased PTH
binding to osteoblast-like cells compared to pH 7.4 [141]. In our experiments, the
slight local acidification would not be expected to adversely affect differentiation
of mesenchymal cells, which is reported to occur at pH [141] and may even upregulate expression of PTH receptors by cells. However, according to BrandaoBurch’ group, at pH 6,9, acidosis reduced mineralization of bone nodules,
osteoblast alkaline phosphatase activity was reduced, and downregulated
messenger ribonucleic acid (mRNA) for alkaline phosphatase [142].
Two of the biomolecules used were incorporated because of their
osteotropic effects. Many in vitro and in vivo studies have been conducted to
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explain the anabolic effect of intermittent infusion of PTH on bone formation. It is
thought that PTH enhances proliferation of primary osteoblastic cells from
humans and animals [10,65]. In addition, PTH exerts diverse effects on
osteoblast differentiation depending on differentiation stage [13,67,68], and it
stimulates alkaline phosphatase (AP) activity in the mouse osteoblastic cell line
MC3T3-E1 [68]. Simvastatin promotes bone formation both in vitro and in vivo in
animal models associated with increasing BMP-2 transcription [48,51,110].
Devices used in this study were fabricated to fluctuate around daily
between maximum and minimum release of drug and it was expected to be
changed in a regular way.

Ideally, the minimum value of each profile would

decrease to zero, because the adjacent layers do not contain the same
biomolecules. However, low but measurable concentrations of drug were
detected. It is thought that during fabrication of the multilayered devices, some
microspheres in adjacent loaded and blank layers became intermingled under
pressure, resulting in “contamination” of the drug-free layer. If absolutely zero
concentration between peaks was needed, thicker blank layers could be made,
although at the expense of increased overall thickness of the device. In some
release profiles, the last one or two peaks were lower than the first peaks
because the drug could be diffused out before the device degraded through the
PLGA coating. To maintain proper range of concentrations, drug loading of
microspheres used for the last layers could be increased, if necessary, and more
frequent sample collection-not once a day-would give more precise
about release profiles.
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information

All cultures treated with intermittent PTH showed increasing DNA content
and AP activity. Unlike intermittent PTH delivery, exposure to 1 μM of simvastatin
had an adverse effect on DNA content compared to other concentrations. This
result corresponds to our previous findings [46]. Sim/PTH delivery devices
showed higher DNA content and AP activity effect compared to CB/Sim, CB/PTH
devices. This phenomenon results in an additive effect of Sim and PTH. The
mechanism of Sim on bone formation is different from that of PTH. PTH
stimulates multiple intracellular signal pathways, mediated by cAMP, and
activates both protein kinase A (PKA) and C (PKC). However, the roles of each
signal transduction system in osteoblast proliferation and differentiation are
unknown [10]. Sim induces BMP-2 transcription through the inhibition of protein
prenylation in osteoblasts and inhibits HMG-CoA reductase activity, resulting in
the depletion of mevalonate in osteoblasts [51]
One of the polymeric multiple biomolecules delivery systems used a
scaffolds and drug loading methods into scaffolds is that one molecule is mixed
in scaffold and another drug was encapsulated into microspheres. In this method
Mooney’s group investigated dual growth factors delivery using PLGA scaffold for
40 days. Another approach was made by Mikos’ group; they encapsulated dual
growth factors and crosslinked them each other[94]. They seek for the target of
traditional controlled release system-simultaneous sustained release system,
whereas our devices were aimed at short term intermittent delivery.
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4.5 CONCLUSION
By alternatingly CAP and PF-127 microspheres loaded with CB and Sim,
CB and PTH(1-34), or Sim and PTH(1-34), intermittent release with five
distinguishable peaks for each of the two molecules were achieved. In vitro
experiments showed that alternating delivery enhanced bioactivity of osteoblastic
cells. Furthermore, alternating treatment with Sim and PTH(1-34) had an additive
effect on cell responses. Overall, CAP/PF-127 polymer is a useful system for
alternating, intermittent, or sequential delivery of multiple molecules, such as
could be used for treatment of local bone defects.

Copyright © Ju Hyeong Jeon 2007
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CONCLUSION
Using the association polymer system of CAP and PF-127, intermittent
release profiles of Sim, PTH (1-34), Sim/CB, PTH/CB, and Sim/PTH were
achieved. Release profiles can be controlled by altering CAP/PF-127 blending
ratio, number of layers, and erosion conditions. From the results of these studies
we find many evidences to support the hypothesis that cell responses to Sim and
PTH containing devices depended on the mode of drug release. Sim treatments
promoted osteoblastic activities and bone formation and PTH treatments
enhanced osteoblastic activities compared to control cultures. Intermittently
delivered Sim showed a greater anabolic effect in vitro and in vivo than sustained
delivery. Combined devices with CB/Sim, CB/PTH and Sim/PTH showed five
distinct peaks for each drug. All cultures treated with multiple molecules showed
enhanced osteoblastic activity, and cultures with alternating Sim and PTH
showed higher osteoblastic activities than Sim or PTH alone. It was clear that
there was additive effect in Sim and PTH combined treatments. Consequently,
these devices may lead to better treatments for local bone regeneration.
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